RAD Security, a San Francisco-based provider of security for cloud-focused infrastructure, raised $14 million in Series A ...
Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...
The FDA announcement confirms that the U.S. supply of both prescription-only drugs now meets or exceeds the current and ...
The U.S. FDA approved 12 drugs in January, falling below the 2024 monthly average of 19. Only three new molecular entities received approval, trailing the yearly average of just over four per month.
Shares of Vertex Pharmaceuticals Inc. VRTX rallied 1.82% to $480.33 Thursday, on what proved to be an all-around grim trading ...
Barchart on MSN4d
Are Wall Street Analysts Predicting Vertex Pharmaceuticals Stock Will Climb or Sink?With a market cap of $118.7 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a global biotechnology leader specializing ...
U.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated ...
AlgoTherapeutix blames a “strong placebo effect” for the mid-stage failure for its pain gel ATX01, but the company still ...
At a time when many life sciences companies are shrinking their workforce, Vertex Pharmaceuticals Inc. has once again grown ...
6d
The high cost of sickle cell gene therapies is pushing private insurers and Medicaid programs to develop new payment models.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback